Cofoe Medical Technology Co., Ltd.

Date of Prospectus: April 27, 2026

Cofoe Medical Technology Co., Ltd. Launches Hong Kong IPO: Key Details, Growth Prospects, and Investor Insights

Cofoe Medical Technology Co., Ltd. is undertaking a highly anticipated Hong Kong IPO with a substantial global offering. This in-depth analysis covers the offer structure, key financials, investor participation, company fundamentals, and actionable insights for institutional and retail investors considering this opportunity in the medical technology sector.

IPO Snapshot: Key Offer Details for Cofoe Medical Technology

Cofoe Medical Technology Co., Ltd. seeks to list H Shares on the Hong Kong Stock Exchange under the symbol 1187. The IPO represents a significant capital raise, structured to attract both institutional and retail investors.

Offer Price Determination: The final offer price will not exceed HK\$39.33 and will be set by reference to the closing price of the A Shares on the Shenzhen Stock Exchange prior to the price determination date. Applicants must pay the maximum price plus applicable fees, with refunds in case of a lower final price [[2]], [[5]].

Public Offering Structure:

• Hong Kong Public Offering: Initially 2,700,000 H Shares (10% of total, subject to reallocation up to 15%)
• International Offering: 24,300,000 H Shares (90% of total, subject to reallocation)

Trading Board Lot: 100 H Shares per lot [[10]].

Use of Proceeds: Capital for Strategic Growth

While the exact allocation of IPO proceeds is not quantified in the available summary, the structure and timing of the offering suggest a strong growth-driven rationale. The company is leveraging the listing to fuel expansion, enhance its market position, and potentially invest in R&D, capacity additions, or working capital. This growth orientation is reinforced by the absence of any mention of debt repayment or deleveraging focus in the announcement [[2]], [[5]].

Placement Breakdown: Public and Institutional Participation

• Hong Kong Public Offering: Up to 15% of Offer Shares may be allocated here in the event of strong demand and reallocation [[5]].
• International Offering: At least 85% of Offer Shares for institutional and international investors, with flexibility for reallocation.
• No public offer in the United States. All shares are offered and sold outside the US in reliance on Regulation S [[1]], [[2]].

Investor Participation & Book Quality

Bookrunners and underwriters are authorized to reallocate shares between the international and Hong Kong public tranches based on demand. The presence of major international coordinators and underwriters may indicate a broad institutional distribution and potentially strong book quality. However, specific anchor or cornerstone investors, tranche allocations, or subscription multiples are not disclosed in the summary [[5]].

Deal Parties and Global Offering Structure

High-profile financial institutions are leading the offering:

• Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers: Huatai Financial Holdings (Hong Kong) Limited, BNP Paribas Securities (Asia) Limited
• Other Overall Coordinator, Joint Global Coordinator, Joint Bookrunner, and Joint Lead Manager: Futu Securities International (Hong Kong) Limited [[2]]

Stabilization and Over-allotment: No explicit mention of stabilization or over-allotment (greenshoe) options in the summary.

Implication: The involvement of these well-known institutions supports confidence in the offering’s distribution, pricing, and potential aftermarket support [[2]].

Company Overview: Cofoe Medical Technology’s Business Model and Market Position

Cofoe Medical Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. The company is positioned in the medical technology sector, focusing on the design, manufacture, and distribution of medical devices and products. While the summary does not provide a detailed business breakdown, the name and sector strongly imply a product-based business model with revenue from device sales, likely targeting healthcare providers, hospitals, and clinics across China and potentially internationally [[2]].

Geographical Focus: Mainland China, with expansion through an H-share listing in Hong Kong.

Market Position and Competitive Advantages

Cofoe Medical Technology is leveraging its brand and market expertise to capture growth in the medical device segment. The listing’s timing and substantial offer size underline the company’s ambition to reinforce its competitive position. Exact market share, revenue ranking, or industry size figures are not disclosed in the summary [[2]].

Management Team

• Chairman and Executive Director: Mr. ZHANG Min
• Executive Directors: Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao, Mr. HE Bangjie
• Independent Non-Executive Directors: Mr. NING Huabo, Ms. SHEN Nan, Mr. Zhou Rong

The leadership team includes both seasoned executives and independent oversight, supporting governance and operational execution [[10]].

Sector Trends, IPO Timing, and Market Environment

The IPO comes amid a dynamic period for medical technology in China, with increasing demand for medical devices and regulatory support for innovation in the healthcare sector. The company is capitalizing on these sectoral tailwinds and the favorable Hong Kong IPO window.

Key IPO Dates:

• Application Period Opens: 9:00 a.m., Monday, April 27, 2026
• Application Period Closes: 12:00 noon, Thursday, April 30, 2026
• Price Determination: No later than 12:00 noon, Monday, May 4, 2026
• Results Announcement: No later than 11:00 p.m., Tuesday, May 5, 2026
• Listing/Trading Commences: 9:00 a.m., Wednesday, May 6, 2026 [[6]], [[7]]

Market Environment: The company cites robust demand drivers and a supportive regulatory climate, without referencing specific macroeconomic indicators in the summary. The IPO’s timing is positioned to capture investor appetite for healthcare and technology growth stories [[6]].

Key Risk Factors

Risks highlighted include:

• Market and Regulatory Risk: The offer is subject to the conditions set out by the Stock Exchange and may be terminated if certain events occur before trading commences.
• Jurisdictional Risk: The shares are not offered in the United States or other restricted jurisdictions, and compliance with relevant regulations is required.
• Application Risk: Applications for numbers of shares outside the prescribed range will be rejected.
• Settlement Risk: Investors trading before share certificates are validated do so at their own risk [[1]], [[5]], [[10]].

Other quantified exposures, customer/supplier concentration, or FX/commodity risk are not disclosed in this summary.

Growth Strategy

The company is pursuing a growth-driven strategy, as inferred from the use of proceeds and the scale of the offering. The capital raised will likely support expansion, capacity additions, and further innovation in product offerings [[2]].

Ownership & Lock-ups

Shareholding structure and lock-up periods are not detailed in the summary. The board of directors and key executive names are disclosed [[10]].

Listing Outlook: Investor Implications and First-Day Trading Prospects

Based solely on disclosed facts, the Cofoe Medical Technology IPO demonstrates several strengths:

• Robust offer size and high-profile underwriter group indicate institutional confidence and potential aftermarket stability.
• Sector tailwinds and growth-driven use of capital support a positive investment thesis.
• Absence of explicit oversubscription or anchor investor data means book quality must be inferred from the involvement of lead banks and the offer structure.

Conclusion: The IPO appears worth considering for investors seeking exposure to China’s medical technology growth story, with strong support from global coordinators and a well-defined offer structure. First-day trading is likely to be robust — especially if the retail and institutional tranches see significant demand — and aftermarket support is probable due to the sponsor group. The likely trading range will initially reflect the offer price, with upside potential if market conditions remain constructive and the company’s growth narrative resonates with investors [[2]], [[5]].

Prospectus Access

The full prospectus and official announcements can be found at www.cofoe.com.cn and www.hkexnews.hk.

How to Apply: Application Channels and Timeline

Investors can apply via two primary channels:

Minimum Application: 100 H Shares, in prescribed multiples only. Applications for other amounts will be rejected. Payment must be made in full at the time of application, including all fees and levies [[3]], [[4]], [[9]].

For further information, refer to www.hkeipo.hk and your broker/custodian.